Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

U.S. Health Secretary Robert F. Kennedy Jr’s newly appointed Advisory Committee on Immunization Practices (ACIP) upheld ...